Business
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 7756U ValiRx PLC 17 July 2018 \n\n \n \n \n \nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\n \nUS PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301\n \n\"DELIVERING VALUE & MARKET OPPORTUNITY FOR \nVALIRX'S ENDOMETRIOSIS PROGRAMME\"\n \nLondon, UK., 17 July 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the United States of America patent and trademark office has granted a US Patent for ValiRx's pre-clinical therapeutic compound, VAL301, for the treatment of the gynaecological disorder, endometriosis or hormone induced abnormal cell growth in women, for which there is substantial global unmet medical need. According to DelveInsight, the endometriosis market is predicted to reach $1.91 billion by 2023. \n \n \nThe patent for VAL301 entitled: \"Inhibitors of the interaction between a src family kinase and an androgen receptor of estradiol receptor for the treatment of endometrioses,\" now provides protection for ValiRx for this indication in the world's largest pharmaceutical market.\n \nEndometriosis occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus. The resulting symptoms are debilitating for an estimated 1 in 10 women in the United States and an estimated 200 million women worldwide and the condition represents one of the biggest health issues for females of reproductive age. \n \nThe symptoms include inter alia inflammation, severe cramps, heavy and prolonged menstrual flow, nausea and vomiting, chronic fatigue, long-term pelvic pain and infertility. Currently, there is no known cause of endometriosis, and because the development of the condition is poorly understood, there are no known ways to cure or prevent it. Its management is often hit or miss, and sometimes includes multiple surgeries and hormonal treatment. As such, the condition also has a significant economic impact. \n \nVAL301 has evolved from the Company's peptide (VAL201), which has been shown to reduce abnormal endometrial growth, whilst leaving other hormone-induced activities working normally. ValiRx's initial in-vitro results show a reduction in endometrial lesion size d...